Similarly, nivolumab (anti-PD-1 antibody) and ipilimumab (anti-CTLA-4 antibody) were evaluated in two separate trials with disappointing efficacy: the TAPUR phase 2 basket study examined individuals in whom all lines of therapy had been exhausted and reported results from patients with mCRC with high tumor mutational burden (TMB; defined as ≥9 mutations per megabase (Mut/Mb)) treated with nivolumab and ipilimumab20. The gene discussed is CTLA4; the disease is neoplasm.